Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL - Hochhaus, Andreas; Réa, Delphine; Boquimpani, Carla; Minami, Yosuke; Cortés, Jorge Eduardo; Hughes, Timothy P.; Apperley, Jane F.; Lomaia, Elza; Voloshin, Sergey; Turkina, Anna; Kim, Dong-Wook; Abdo, Andre; et al. (Leukemia, 2023)
Online veröffentlicht: 30. Januar 2023